NOV 26, 2020 8:25 AM PST

Possible Cardioprotective Effects of the Diabetes Drug Empagliflozin

WRITTEN BY: Jasper Cantrell

Cardiovascular disease and diabetes are often associated with each other, as many issues caused by diabetes promote heart issues. It stands to reason that perhaps a diabetes drug may be able to treat cardiovascular disease.

That is what a team from the Medical University at Innsbruck in Austria thought. The drug empagliflozin is an inhibitor of a protein called sodium-glucose transporter 2 (SGLT2) and is used to treat type 2 diabetes. Surprisingly, empagliflozin has also shown cardioprotective effects in several studies, leading some to wonder if it could be a preventative drug for cardiovascular disease.

The team decided to investigate empagliflozin’s effects as a cardioprotective agent and how it might conduct its protection. The team used a relatively short-term diabetic mouse model for this study, as long-term models can sometimes result in quite variable results.

The expected short-term effects of improved insulin sensitivity were clear from the beginning. Empagliflozin therapy also reduced inflammatory and cardiac fibrosis markers compared to controls. Inflammation can cause blood flow issues in the short term, with fibrosis being a cardiovascular disease where the heart progressively stiffens until heart failure occurs.

The team also observed that a protein marker of mitochondrial mass was upregulated in empagliflozin treated mice. Electron microscopy showed that the mitochondria in the treated mice were markedly different in their structures and size than control diabetic mice. Mitochondria are critical parts of the cell, so any such changes are a big deal.

This short study identified some possible mechanisms by which empagliflozin could act as a cardioprotective agent. The reduced protein inflammatory and fibrosis markers are the clearest sign of the cardioprotective effects of empagliflozin. The mitochondrial effects were interesting, as diabetes often causes abnormal mitochondrial structures. Empagliflozin may alleviate that abnormality to some degree, which could rescue endangered cells (or enable proper cell death if need be). This study wasn’t a comprehensive one, but never the less supplied some idea for future studies to work on.

The study concludes, “Mechanistically, improved mitochondrial ultrastructure, ameliorated over-activation of insulin signaling activity and changed macrophage polarization might contribute to cardioprotective effects of empagliflozin.”

 

Sources: Nature Scientific Reports, MDLinx, Unsplash

About the Author
  • Hey everyone! My name is Jasper and, considering I am pretty new here to Labroots, I figured I would introduce myself. I received my bachelor’s from the University of California at Riverside back in 2016. I started off my career a few years ago with a job at a University over in New York, before moving over into the industry. I'm happy to be writing content for Labroots, and I hope you enjoy it!
You May Also Like
SEP 18, 2020
Clinical & Molecular DX
Open Your Heart to the World's Smallest Diagnostic Probe
SEP 18, 2020
Open Your Heart to the World's Smallest Diagnostic Probe
Certain health conditions require doctors to be able to observe tissues and organs in order to tell what’s wrong. ...
SEP 16, 2020
Neuroscience
Blood Lipid Levels Predict Depression and Anxiety
SEP 16, 2020
Blood Lipid Levels Predict Depression and Anxiety
While people often experience anxiety and depression together, psychiatrists classify them as different disorders. And n ...
SEP 24, 2020
Cardiology
Analyzing Genetic Mutations in Pulmonary Arterial Hypertension
SEP 24, 2020
Analyzing Genetic Mutations in Pulmonary Arterial Hypertension
With the advancement of genomics and genome sequencing, it has become possible for researchers to study diseases down to ...
OCT 27, 2020
Cardiology
Boron Could Prevent Myocardial Fibrosis and Assist in Recovery
OCT 27, 2020
Boron Could Prevent Myocardial Fibrosis and Assist in Recovery
When you pass by the nutrition section at the local grocery store, there is a chance you’ll come across row upon r ...
NOV 24, 2020
Cardiology
Patients on Statins Get the 'Nocebo Effect'
NOV 24, 2020
Patients on Statins Get the 'Nocebo Effect'
Millions of people around the world take statins to treat high cholesterol, which are estimated to reduce the risk of he ...
JAN 12, 2021
Cardiology
SGLT2 Inhibitors Can Reduce the Cardiovascular Risk for Diabetics Being Treated with Insulin
JAN 12, 2021
SGLT2 Inhibitors Can Reduce the Cardiovascular Risk for Diabetics Being Treated with Insulin
One of the biggest problems that come alongside diabetes is the increased risk of cardiovascular disease. Treatment of d ...
Loading Comments...